Please assess the completion status of the following clinical trial:

Trial Title: VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of leukemia or myelodysplastic syndromes (MDS) meeting criteria for 1 of the following:~  * Relapsed or refractory leukemia for which there is no standard therapy anticipated to result in a durable remission~    * Acute myeloid leukemia~   * Acute lymphocytic leukemia~   * Chronic myelogenous leukemia~      * In blast crisis~ * Untreated leukemia and standard therapy is refused~ * Any of the following poor-risk MDS:~    * Refractory anemia with excess blasts (RAEB)~   * RAEB in transformation~   * Chronic myelomonocytic leukemia~* CNS leukemia allowed~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* ALT or AST no greater than 3 times ULN~* Chronic hepatitis allowed~Renal~* Creatinine no greater than 2.0 mg/dL~Cardiovascular~* No active heart disease~* No myocardial infarction within the past 3 months~* No symptomatic coronary artery disease~* No arrhythmias uncontrolled by medication~* No uncontrolled congestive heart failure~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No persistent chronic toxic effects from prior chemotherapy greater than grade 1~* No uncontrolled active infection~  * Infections under control and under active treatment with antibiotics allowed~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* At least 48 hours since prior hydroxyurea~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* At least 2 weeks since prior myelosuppressive cytotoxic agents (in the absence of rapidly progressing disease)~* No other concurrent standard or investigational treatment for leukemia~* No concurrent disulfiram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).